| Name | Title | Contact Details |
|---|
Onsite Partners, Inc. is a holding company of behavioral services organizations: Onsite Workshops, Milestones, and Onsite at The Oaks. The Onsite family of brands provides services to thousands of clients annually from the United States and Europe, through in-person and virtual settings. Through these companies, Onsite curates transformational emotional health experiences that combine some of the best therapeutic and clinical minds in the country with its signature healing hospitality. Recently Onsite launched a series of virtual emotional health courses and will be expanding this platform in 2021. Onsite offers experiential group programs, counseling intensives, digital courses, and innovative residential trauma treatment that bolster empathy, self-awareness, compassion, and resilience. Onsite`s mission is to change lives through enhanced emotional health. Onsite`s work has been featured on 20/20, Good Morning America, New York Times, Wall Street Journal, Marie Claire, People, Dr. Phil Show, and The Doctors.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Health Information Technology Care is a Petaluma, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Great Plains Orthotics and Prosthetics, Inc. is a Ames, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DOWNTOWN BRONX MEDICAL ASSOCIATES is a Bronx, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.